

- Fortin, Pierre** (Pharmaceutical Manufacturers Association of Canada)
Patent Act (amdt.)(Bill C-22), 3:4, 41-2, 49-51, 60, 63, 71-3
- France** *see* Drug Prices Review Board—Regulatory powers, Price evasion tendency
- Frank W. Horner Inc.**
Canadian origin, 6:51
- Frankford, Robert** (Ontario Medical Reform Group)
Patent Act (amdt.)(Bill C-22), 9:4, 42-53
- Fraser Institute** *see* Drugs and pharmaceuticals—Costs/prices
- Free enterprise system**
Fair pricing, 3:40-1; 12:56; 13:30; 15:36
- Free trade, Canada-United States negotiations**
Davidson article, federal drug law changes as bargaining chip, 15:97
Government under pressure, 10:21, 27; 13:36-7; 14:20-1, 25-6, 32-3, 45; 15:65
Health care, non-negotiable, 15:56
See also Canadian Chamber of Commerce; Drugs and pharmaceuticals—United States
- Friedman, Milton** *see* Drug patents
- Frith, Hon. Douglas C.** *see* Bill C-22—References, Liberal government
- Gagné, Jacques** (Coalition nationale pour la recherche en science de la santé)
Patent Act (amdt.)(Bill C-22), 11:3, 38-51
References, background/credentials, 11:41, 47
- Gariépy, André** (Consumer and Corporate Affairs Department)
Patent Act (amdt.)(Bill C-22), 16:3, 7, 26-9, 32-5, 37, 39, 41-4, 46-57; 17:15, 47-8
- Garvin, Dr. Robert T.** (Cangene Corp.)
Patent Act (amdt.)(Bill C-22), 8:4, 36-7, 40, 42-5, 48
- GATT** *see* General Agreement on Tariffs and Trade
- Geekie, Doug** (Canadian Medical Association)
Patent Act (amdt.)(Bill C-22), 13:3, 27-8, 30-1
- General Agreement on Tariffs and Trade** *see* Generic drugs—Compulsory licensing
- Generic drugs**, 3:19; 8:6
Banning, Manitoba cabinet ministers misinformation campaign, etc., 1:28; 3:30-1, 50
Compulsory licensing, Bill C-22 effect, 1:11-2, 14; 3:8, 16, 29, 47; 6:33, 49, 75, 79; 7:4-5; 8:9, 60; 9:51-3; 10:30
Benefits/drawbacks, 3:6, 16-7; 5:40-1; 7:15; 9:45; 11:14, 19; 14:7, 10-1, 21-2
General Agreement on Tariffs and Trade, Paris Convention, etc., violations, 3:53-4; 5:26; 6:12-3; 8:19-20; 10:16; 11:43; 12:60; 15:55, 59; 16:76-82
Information, requesting, 8:20, 28
Notice of compliance, transitional arrangements, pipeline drugs, etc., 1:15, 31-2; 5:11-2, 14; 6:85-6; 12:11, 74
Ontario Hospital Association study, 3:16
Price control, policy tradition, 5:12
United States comparison, 3:23
Industry/research and development, innovation, 3:26, 33-4, 62; 6:37; 9:12; 12:12; 14:29-30; 15:27-8, 83-4
Canadian ownership, extent, 15:66-7
Charitable goals, public ownership factor, etc., 10:18; 11:75-6
- Generic drugs—Cont.**
Industry/research and development, innovation—*Cont.*
Clinical research vs quality control only, 5:24; 10:40; 11:14-5
Company commitments, demanding, proposal, 12:46
Employment, 10:18-9
Post-market research, lacking, 6:37; 13:29
United States, growth, 12:74
Intellectual property, piracy allegations, 3:24, 26-7, 44-5; 6:37, 69, 77, 85; 8:64; 9:13; 10:18; 11:15, 38-41, 78; 12:31; 15:85, 92, 96, 99; 16:25
Tagamet/Smith, Kline and French example, 3:47-8, 66
Yeutter quotation, 10:27-8
Legislation, Bill C-22 effect, 3:27; 7:5; 11:67; 14:11; 15:32, 86
See also Generic drugs—Prices
Manufactured in Canada, 10 year exclusivity period, reducing to seven years, Bill C-22 proposing, 1:12-5; 3:11, 33, 48; 5:31; 15:87-8
Market entry timeframe, 1:11-2; 3:20, 33, 39-40, 71; 5:12, 17; 6:82-3, 86; 14:9
Key statement, 3:50
Market share, 1:12; 3:20, 23, 27, 33, 62; 11:56, 69
National Health and Welfare Department, Health Protection Branch clearance delays, 3:20, 29-30; 6:82-3
Prices
Brand name drugs comparing, 12:69-70
Legislation, Bill C-22 effect, 3:71; 8:66
Product range, restricted to "winners", 3:21, 26, 40, 60; 6:70, 82; 8:14-5; 9:18; 12:72-3; 15:65
Profit margins, 15:98-9
Royalty payments, increasing, Eastman report research fund proposal, 5:19-20, 22; 6:41, 63, 69-70; 8:7, 15, 24, 61, 64; 9:16, 45; 10:9; 11:6-7, 14-5, 77; 12:11
Scientific Research Tax Credit Program comparison, 9:19; 12:49
United Kingdom, comparison, 6:42
Sales, 1985, 3:23; 8:61, 67
Side-effects/quality/substitutions, etc., 6:35, 37, 40-1, 47; 11:80; 12:27, 31, 41-2; 13:21, 25; 11:27-8; 15:56-7, 63-4
United States, policy change favouring, contemplated, 6:54
See also Generic drugs—Compulsory licensing—Industry
See also Drug plans; Drugs and pharmaceuticals—Single-source; Health care—Hospitals; McMaster University Faculty of Health Sciences; Ontario Medical Reform Group; Senior citizens
- Genetic animals**
Patent protection lacking, 5:39
- Geriatrics**
Research, current, 15:53-4
- Glaxo Canada Limited** *see* Smith, Kline and French Canada Ltd.
- Globe and Mail, The** *see* Brand name drugs—Profit levels, Excess cash
- GNP** *see* Gross National Product
- Gorecki, Paul** (Individual presentation)
Patent Act (amdt.)(Bill C-22), 14:3, 67-76
References, background/credentials, 14:69, 72-3
- Government departments appearing** *see* Witnesses
- Governor in Council** *see* Drugs patents—Applications; Drug Prices Review Board—Appointments process; Patent Act (amdt.)(Bill C-22)—References, Regulations; Patent Co-operation Treaty
- "Green book"** *see* Drugs and pharmaceuticals—Costs/prices, Restrictive Trade Practices Commission